BioMarin Pharmaceutical Inc.
BMRN NASDAQHealthcare ★★★★★Latest Earnings Above forecast↑
Date
Aug 6, 2026
ET
EPS Est.
0.95
EPS Actual
1.20
Revenue Est.
$932M
Revenue Actual
$989.7M
Next Earnings Report
Date
Oct 26, 2026 · Mon
Time
After-market
Fiscal Period
FY2026 Q3
EPS Est.
1.38
Revenue Est.
$1.03B
Company Overview
BioMarin Pharmaceutical Inc. (ticker BMRN) is listed on NASDAQ with a market cap of about $12.89B. Its next earnings report (FY2026 Q3) is expected on Oct 26, 2026 (ET), After-market, with consensus EPS of 1.38. In the last 15 reported quarters, EPS beat consensus estimates 10 times.
Actual EPS TrendRecently15Term · Feb 27, 2023 → Aug 6, 2026
Feb 27, 2023Range: -0.24 ~ 1.23Aug 6, 2026
Earnings History
| Date | Fiscal Period | EPS Est. | EPS Actual | Revenue Est. | Revenue Actual |
|---|---|---|---|---|---|
| Aug 6, 2026 | -- | 0.95 | Above forecast↑1.20 | $932M | $989.7M |
| May 4, 2026 | -- | 0.78 | 0.76 | $752.5M | $766M |
| Feb 23, 2026 | -- | 0.17 | Below forecast↓-0.24 | $833.7M | $874.6M |
| Oct 27, 2025 | -- | -0.15 | -0.16 | $777.5M | $776.1M |
| Aug 4, 2025 | -- | 0.86 | Above forecast↑1.23 | $761.9M | $825M |
| May 1, 2025 | -- | 0.71 | Above forecast↑0.97 | $738.7M | $745.1M |
| Feb 19, 2025 | -- | 0.54 | Above forecast↑0.64 | $712.3M | $747M |
| Oct 29, 2024 | -- | 0.53 | 0.55 | $703.4M | $745.7M |
| Aug 5, 2024 | -- | 0.36 | Above forecast↑0.55 | $664M | $712M |
| Apr 24, 2024 | -- | 0.31 | Above forecast↑0.46 | $651.8M | $648.8M |
| Feb 22, 2024 | -- | 0.20 | Below forecast↓0.11 | $638.8M | $646.2M |
| Nov 1, 2023 | -- | 0.22 | 0.21 | $603.8M | $581.3M |
| Jul 31, 2023 | -- | 0.21 | Above forecast↑0.29 | $595.2M | $595.3M |
| Apr 26, 2023 | -- | 0.16 | Above forecast↑0.27 | $570.4M | $596.4M |
| Feb 27, 2023 | -- | -0.07 | Above forecast↑0.11 | $537.6M | $537.5M |
Original Filings (SEC)
8-K2026-08-18 ↗
10-Q2026-08-06 ↗
8-K2026-08-06 ↗
8-K2026-06-04 ↗
10-Q2026-05-05 ↗
8-K2026-05-04 ↗
8-K2026-04-27 ↗
8-K2026-04-23 ↗
Links point to the company's original filings on the U.S. Securities and Exchange Commission (SEC) website.
Report dates are US trading days (Eastern Time); EPS and revenue estimates are market consensus, in USD. This page is for reference only and does not constitute investment advice.
